InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025
InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its...
China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA
China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura...
Junshi Biosciences’ Toripalimab Secures EC Nod for Two Cancer Indications
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Allist Pharma’s Partner Abbisko Receives NMPA Green Light for NSCLC Drug Trial
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...
Huadong Medicine’s V20 Device Receives NMPA Approval for Market Launch
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Winner Medical Expands Global Footprint with Acquisition of Global Resources International
China-based Winner Medical Co., Ltd., a prominent manufacturer of disposable medical products, has announced the...
AstraZeneca Launches South Korea Innovation Program with Focus on Chinese Market Expansion
AstraZeneca plc (LON: AZN, Nasdaq: AZN), a UK-based pharmaceutical and biopharmaceutical company, is reportedly launching...
UCB’s Bimzelx Gains FDA Approval for Three Additional Autoimmune Indications
Belgium-based biopharmaceutical company UCB has announced that the US Food and Drug Administration (FDA) has...
HBOW Bio’s First-in-Class Tumor Imaging Drug NC527-X Receives NMPA Clinical Trial Approval
HBOW Bio, a precision oncology company supported by Sherpa Healthcare Partners, has secured clinical trial...
CDE’s BL-B01D1 on Track for Breakthrough Therapy Designations for EGFR Wild-Type and Mutant NSCLC
The Center for Drug Evaluation (CDE) has indicated on its website that two indications for...
Acotec Scientific’s Heart Valve Balloon Dilatation Catheter RunFlow Wins NMPA Approval
Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...
AimingMed Technologies Partners with RekeyMed to Advance Biotech and Organoid Innovations
Hangzhou AimingMed Technologies Co., Ltd., a leading organoid specialist based in China, has entered into...
Shanghai Fudan-Zhangjiang Enrolls First Patient in U.S. Phase II Study for Port Wine Stain Treatment
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a leading biopharmaceutical company based in...
Antengene’s Xpovio Receives NDA Approval in Thailand for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Wuhan YZY Biopharma Presents M701 Interim Results at 2024 ESMO Congress for NSCLC-Related Pleural Effusion
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
Allist Pharmaceuticals’ EGFR Inhibitor AST2303 Approved for Clinical Trial in NSCLC by NMPA
Allist Pharmaceuticals Inc. (SHA: 688578), a Shanghai-based pharmaceutical company, has announced that it has received...
Haisco Pharmaceutical’s HSK21542 for Itching in Dialysis Patients Receives NMPA Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a prominent Chinese pharmaceutical company, has announced that...
CDE Lists Five Drugs and One Companion Diagnostic for Priority Review Status
The Center for Drug Evaluation (CDE) has indicated on its website that five investigational drugs...
Hainan Province Approves Heart-Lung Walking Test Analysis Software as Category II Device
The Hainan Medical Products Administration has granted marketing approval to a heart-lung walking test data...
Frontera Therapeutics Receives FDA Approval for Phase II Study of First Chinese rAAV Gene Therapy
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...